COMP <GO>
BFRG vs MBRX // 10Y YIELD & FRED MACRO BETA
Bullfrog AI Holdings Inc. (NASDAQ) VS. Moleculin Biotech Inc. (NASDAQ) • 15-METRIC TALLY: BFRG 1
— MBRX 1
■ METRIC PARITY
LAST: $0.51 (+3.88%) • MKT CAP: $9.4M
macro-sensitivity
—
LAST: $8.72 (-0.29%) • MKT CAP: $9.2M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BFRG VS. MBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BFRG | MBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 44.6 | -1.19 | MBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.4M | $9.2M | $226.1K | BFRG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BFRG REV | MBRX REV | BFRG GROSS % | MBRX GROSS % | BFRG FCF | MBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.7K | $0 | 18.8% | — | -$5.5M | -$22.7M |
| FY 2024 | $0 | $0 | — | — | -$5.6M | -$23.9M |
| FY 2023 | $65.0K | $0 | — | — | -$6.0M | -$23.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BFRG // BETA —
MBRX // BETA —